Ramatroban

Summary

Ramatroban (CHEMBL361812) is an approved small molecule targeting PTGDR2; indicated across 2 conditions including asthma and severe acute respiratory syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Targets: 1 (PTGDR2)
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 416.5 Da · C21H21FN2O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL361812
Name	Ramatroban
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	123879
Molecular formula	C21H21FN2O4S
Molecular weight	416.5
InChIKey	LDXDSHIEDAPSSA-OAHLLOKOSA-N

SMILES: C1CC2=C(C[C@@H]1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O

IUPAC name: 3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid

Also known as: BAY-U-3405, Baynas, EN-137774, Ramatroban, ramatroban, SID50112772, SID144206069, SID170465980, SID174006902, RAMATROBAN

Patent coverage: 809 distinct patent families (3,250 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,212 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PTGDR2	DP2 receptor	Antagonist	8.1	0%	Q9Y5Y4

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Cholecystokinin receptor type A, D(1A) dopamine receptor, Thromboxane A2 receptor, Cytochrome P450 2C9, Prostaglandin D2 receptor, Prostaglandin D2 receptor 2, Bile salt export pump.

Bioactivity

ChEMBL activities: 25 potent at pChembl ≥ 5 of 30 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TBXA2R	9.24	Ki	0.58	nM	CHEMBL_ACT_5134848
PTGDR2	8.37	Ki	4.3	nM	CHEMBL_ACT_1516936
TBXA2R	8.35	Ki	4.5	nM	CHEMBL_ACT_1516939
TBXA2R	8.08	IC50	8.4	nM	CHEMBL_ACT_1516941
TBXA2R	8.02	IC50	9.6	nM	CHEMBL_ACT_1516940
TBXA2R	7.85	IC50	14	nM	CHEMBL_ACT_2706511
TBXA2R	7.75	Ki	18	nM	CHEMBL_ACT_1428603
PTGDR2	7.68	IC50	21	nM	CHEMBL_ACT_2714937
PTGDR2	7.55	IC50	28	nM	CHEMBL_ACT_1516938
PTGDR2	7.54	IC50	29	nM	CHEMBL_ACT_1516937
TBXA2R	7.51	AC50	31.1	nM	CHEMBL_ACT_25155526
TBXA2R	7.4	AC50	40	nM	CHEMBL_ACT_25198237
PTGDR2	7.14	Ki	73	nM	CHEMBL_ACT_2714934
PTGDR2	7.11	IC50	77	nM	CHEMBL_ACT_5314871
PTGDR2	6.86	Ki	137	nM	CHEMBL_ACT_5134840
PTGDR2	6.77	IC50	169	nM	CHEMBL_ACT_2153957
PTGDR2	6.71	IC50	195	nM	CHEMBL_ACT_2714938
PTGDR2	6.68	IC50	210	nM	CHEMBL_ACT_2714935
PTGDR2	6.54	Ki	290	nM	CHEMBL_ACT_1428599
PTGDR2	6.54	Ki	290	nM	CHEMBL_ACT_1428600
PTGDR2	6.51	IC50	311	nM	CHEMBL_ACT_2706463
PTGDR2	6.47	Ki	340	nM	CHEMBL_ACT_1428601
PTGDR2	6.34	IC50	461	nM	CHEMBL_ACT_5295534
PTGDR2	6.12	IC50	754	nM	CHEMBL_ACT_2706475
DRD1	5.22	AC50	6010	nM	CHEMBL_ACT_25114827

Target pathways

Aggregated over 1 target gene(s): PTGDR2.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Prostanoid ligand receptors	1	PTGDR2
G alpha (i) signalling events	1	PTGDR2

Dominant GO biological processes

GO term	Targets
chemotaxis	1
immune response	1
G protein-coupled receptor signaling pathway	1
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	1
neuropeptide signaling pathway	1
calcium-mediated signaling	1
positive regulation of G protein-coupled receptor signaling pathway	1
cellular response to prostaglandin D stimulus	1
negative regulation of male germ cell proliferation	1
signal transduction	1

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
asthma	2	MONDO:0004979	MONDO:0004979
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05706454	PHASE2/PHASE3	RECRUITING	Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia
NCT00311051	PHASE2/PHASE3	WITHDRAWN	Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

10 molecules share ≥1 primary target. Top 10 by shared-target count:

Molecule	Source	Status	Shared targets
INDOMETHACIN	ChEMBL + PubChem	Phase 4 (approved)	PTGDR2
LAROPIPRANT	ChEMBL	Phase 4 (approved)	PTGDR2
FEVIPIPRANT	ChEMBL	Phase 3	PTGDR2
SETIPIPRANT	ChEMBL	Phase 3	PTGDR2
TIMAPIPRANT	ChEMBL	Phase 3	PTGDR2
AZD1981	ChEMBL	Phase 2	PTGDR2
BI-671800	ChEMBL	Phase 2	PTGDR2
FENTIAZAC	ChEMBL	Phase 2	PTGDR2
QAV680	ChEMBL	Phase 2	PTGDR2
VIDUPIPRANT	ChEMBL	Phase 2	PTGDR2